RY 174.39 2.4016% SHOP 149.115 2.5974% TD-PFM 24.63 -0.0811% TD-PFL 24.7 0.2028% TD 78.325 0.1214% ENB 60.6 1.3039% BN 80.4 1.9787% TRI 226.27 0.7525% CNQ 48.285 2.2771% CP 104.53 1.6038% CNR 151.74 1.5459% BMO 132.69 0.9203% BNS 78.845 0.1715% CSU 4600.2002 2.157% CM 91.15 0.474% MFC 45.79 1.6878% ATD 78.38 1.5285% NGT 60.14 0.0499% TRP 70.15 1.977% SU 57.44 0.5954%
Last update at 2024-11-21T19:41:00Z
Bausch Health call volume above normal and directionally bullish
Sat 19 Oct 24, 06:45 PMBausch Health Companies Inc. (BHC): A Top Pick in Carl Icahn’s Stock Portfolio
Sat 28 Sep 24, 11:07 AMHere's Why Bausch Health Stock Gained 14.7% in a Week
Mon 23 Sep 24, 05:43 PM3 Stocks Billionaires Are Buying Now
Sun 22 Sep 24, 04:00 PMBausch (BHC) Surges 11.7%: Is This an Indication of Further Gains?
Thu 19 Sep 24, 11:02 AMBausch Health Taps Jefferies to Refinance Debt, Aid Spinoff
Tue 17 Sep 24, 10:40 PMBausch + Lomb (BLCO) Surges 14.5%: Is This an Indication of Further Gains?
Tue 17 Sep 24, 08:12 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -129.00000M | -1024.00000M | -934.00000M | -1837.00000M | -4154.00000M |
| Minority interest | -13.00000M | -11.00000M | 70.00M | 73.00M | 82.00M |
| Net income | -212.00000M | -937.00000M | -559.00000M | -1783.00000M | -4148.00000M |
| Selling general administrative | 2625.00M | 2624.00M | 2367.00M | 2554.00M | 2473.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 5760.00M | 6040.00M | 5778.00M | 6251.00M | 6029.00M |
| Reconciled depreciation | 1394.00M | 1375.00M | 1825.00M | 2075.00M | 2819.00M |
| Ebit | 1370.00M | 1210.00M | 676.00M | -73.00000M | -2473.00000M |
| Ebitda | 2585.00M | 2585.00M | 2518.00M | 1824.00M | 346.00M |
| Depreciation and amortization | 1215.00M | 1375.00M | 1842.00M | 1897.00M | 2819.00M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 1370.00M | 1210.00M | 676.00M | -73.00000M | -2384.00000M |
| Other operating expenses | 6768.00M | 7231.00M | 6713.00M | 8686.00M | 7882.00M |
| Interest expense | 1464.00M | 1426.00M | 1534.00M | 1612.00M | 1685.00M |
| Tax provision | 83.00M | -87.00000M | -375.00000M | -54.00000M | -10.00000M |
| Interest income | 1458.00M | 1412.00M | 13.00M | 1592.00M | 1651.00M |
| Net interest income | -1450.00000M | -1419.00000M | -1521.00000M | -1600.00000M | -1674.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 83.00M | -87.00000M | -375.00000M | -54.00000M | -10.00000M |
| Total revenue | 8124.00M | 8434.00M | 8027.00M | 8601.00M | 8380.00M |
| Total operating expenses | 4404.00M | 4837.00M | 4464.00M | 6336.00M | 5531.00M |
| Cost of revenue | 2364.00M | 2394.00M | 2249.00M | 2350.00M | 2351.00M |
| Total other income expense net | -1499.00000M | -2234.00000M | -1610.00000M | -1764.00000M | -1770.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -212.00000M | -937.00000M | -559.00000M | -1783.00000M | -4144.00000M |
| Net income applicable to common shares | -225.00000M | -948.00000M | -560.00000M | -1788.00000M | -4148.00000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 27350.00M | 25686.00M | 29202.00M | 31199.00M | 33863.00M |
| Intangible assets | 6456.00M | 5800.00M | 6948.00M | 8445.00M | 10201.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1092.00M | 776.00M | 720.00M | 855.00M | 779.00M |
| Total liab | 27432.00M | 25426.00M | 29236.00M | 30594.00M | 32727.00M |
| Total stockholder equity | -1022.00000M | -692.00000M | -106.00000M | 535.00M | 1063.00M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1041.00M | 2988.00M | 4791.00M | 4576.00M | 4511.00M |
| Common stock | 10423.00M | 10391.00M | 10317.00M | 10227.00M | 10172.00M |
| Capital stock | 10423.00M | 10391.00M | 10317.00M | 10227.00M | 10172.00M |
| Retained earnings | -9778.00000M | -9186.00000M | -8961.00000M | -8013.00000M | -7452.00000M |
| Other liab | - | 967.00M | 1170.00M | 1529.00M | 1578.00M |
| Good will | 11183.00M | 11547.00M | 12457.00M | 13044.00M | 13126.00M |
| Other assets | - | 2271.00M | 2345.00M | 2542.00M | 1830.00M |
| Cash | 947.00M | 564.00M | 582.00M | 605.00M | 3243.00M |
| Cash and equivalents | - | 564.00M | 582.00M | 605.00M | 3243.00M |
| Total current liabilities | 4302.00M | 3941.00M | 5198.00M | 4913.00M | 6248.00M |
| Current deferred revenue | 2092.00M | - | - | - | 2394.00M |
| Net debt | 21441.00M | 20202.00M | 22072.00M | 23320.00M | 22652.00M |
| Short term debt | 450.00M | 432.00M | 0.00000M | 1234.00M | 1234.00M |
| Short long term debt | 450.00M | 432.00M | - | - | 1234.00M |
| Short long term debt total | 22388.00M | 20766.00M | 22654.00M | 23925.00M | 25895.00M |
| Other stockholder equity | 214.00M | 159.00M | 462.00M | 454.00M | 429.00M |
| Property plant equipment | - | 1821.00M | 1845.00M | 1826.00M | 1737.00M |
| Total current assets | 5596.00M | 4247.00M | 5607.00M | 5342.00M | 6969.00M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -18039.00000M | -19511.00000M | -20954.00000M | -22264.00000M |
| Short term investments | - | - | - | - | - |
| Net receivables | 1998.00M | 1790.00M | 1775.00M | 1577.00M | 1839.00M |
| Long term debt | 21938.00M | 20334.00M | 22654.00M | 23925.00M | 24661.00M |
| Inventory | 1544.00M | 1090.00M | 993.00M | 1094.00M | 1107.00M |
| Accounts payable | 719.00M | 521.00M | 407.00M | 337.00M | 503.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -1881.00000M | -2056.00000M | -1924.00000M | -2133.00000M | -2086.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 10227.00M | 10172.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 307.00M | 326.00M | 340.00M | 664.00M | 411.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 21754.00M | 21439.00M | 23595.00M | 25857.00M | 26894.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | 20334.00M | 22654.00M | 23925.00M | 24661.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -303.00000M | -4.00000M | -261.00000M | -419.00000M | -196.00000M |
| Change to liabilities | -75.00000M | 121.00M | -471.00000M | -149.00000M | -121.00000M |
| Total cashflows from investing activities | -303.00000M | 409.00M | -261.00000M | -419.00000M | -196.00000M |
| Net borrowings | -1010.00000M | -1340.00000M | -2187.00000M | 1554.00M | -1160.00000M |
| Total cash from financing activities | -474.00000M | -1513.00000M | -2294.00000M | 1443.00M | -1353.00000M |
| Change to operating activities | -66.00000M | -4.00000M | 12.00M | 1.00M | -72.00000M |
| Net income | -212.00000M | -937.00000M | -559.00000M | -1783.00000M | -4144.00000M |
| Change in cash | -1528.00000M | 303.00M | -1428.00000M | 2521.00M | -74.00000M |
| Begin period cash flow | 2119.00M | 1816.00M | 3244.00M | 723.00M | 797.00M |
| End period cash flow | 591.00M | 2119.00M | 1816.00M | 3244.00M | 723.00M |
| Total cash from operating activities | -728.00000M | 1426.00M | 1111.00M | 1501.00M | 1501.00M |
| Issuance of capital stock | 675.00M | - | - | - | - |
| Depreciation | 1394.00M | 1552.00M | 1825.00M | 2075.00M | 2819.00M |
| Other cashflows from investing activities | -35.00000M | 27.00M | 23.00M | 23.00M | 23.00M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -198.00000M | -16.00000M | -77.00000M | -209.00000M | -5.00000M |
| Change to account receivables | -57.00000M | -229.00000M | 170.00M | 39.00M | 216.00M |
| Sale purchase of stock | 675.00M | - | - | - | 2.00M |
| Other cashflows from financing activities | 6697.00M | 1927.00M | 3349.00M | 5861.00M | 8751.00M |
| Change to netincome | -1600.00000M | 895.00M | 151.00M | 1469.00M | 2733.00M |
| Capital expenditures | 268.00M | 283.00M | 309.00M | 278.00M | 235.00M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -396.00000M | -128.00000M | -366.00000M | -318.00000M | 18.00M |
| Stock based compensation | 126.00M | 128.00M | 105.00M | 102.00M | 87.00M |
| Other non cash items | -1464.00000M | 1036.00M | 581.00M | 1655.00M | 2865.00M |
| Free cash flow | -996.00000M | 1143.00M | 802.00M | 1223.00M | 1266.00M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BHC Bausch Health Companies Inc |
-0.11 0.96% | 11.37 | - | 2.23 | 0.50 | 18.74 | 2.56 | 9.13 |
| CURA Curaleaf Holdings Inc. |
-0.175 5.93% | 2.77 | - | 138.89 | 1.62 | 1.66 | 1.73 | 10.18 |
| TLRY Tilray Inc |
0.03 1.38% | 1.83 | - | 1000.00 | 2.17 | 0.36 | 1.69 | -2.299 |
| CRON Cronos Group Inc |
0.06 2.15% | 2.85 | - | - | 10.18 | 0.70 | 0.02 | -1.9458 |
| WEED Canopy Growth Corp |
0.22 4.17% | 5.49 | - | - | 2.77 | 1.22 | 3.58 | -1.5049 |
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
2150 St. ElzEar Boulevard West, Laval, QC, Canada, H7L 4A8
| Name | Title | Year Born |
|---|---|---|
| Mr. Thomas J. Appio | CEO & Director | 1962 |
| Mr. Thomas G. Vadaketh | Exec. VP & CFO | 1963 |
| Mr. Mirza Dautbegovic | Sr. VP & COO | NA |
| Mr. John S. Barresi | Sr. VP, Controller & Chief Accounting Officer | 1973 |
| Dr. Robert F. Butz | VP of Medical & Scientific Affairs | NA |
| Mr. Arthur J. Shannon | Sr. VP and Head of Investor Relations & Global Communications | NA |
| Ms. Seana Carson | Exec. VP & Gen. Counsel | 1972 |
| Ms. Kathleen Fitzpatrick | Sr. VP & Chief HR Officer | NA |
| Dr. Tage Ramakrishna M.D. | Chief Medical Officer and Pres of R&D | 1974 |
| Mr. Jeff Hartness | Sr. VP of Market Access, Commercial Operations & Gov. Affairs | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...